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Abstract Regorafenib (BAY 73-4506, Stivarga® Bayer
HealthCare Pharmaceutical Inc) is an oral multikinase inhib-
itor with a distinct and wide-ranging profile of tyrosine kinase
inhibition, resulting in antiangiogenic and antiproliferative
properties in tumors. Single-agent regorafenib administered
as a 160-mg daily dose for the first 21 days of a 28-day cycle is
approved for use in patients with pretreated metastatic colo-
rectal cancer (mCRC) and gastrointestinal stromal tumor
(GIST) progressing on imatinib and sunitinib, following pub-
lication of data from the phase III CORRECT and GRID
studies respectively. Regorafenib is currently under phase III
investigation in patients with hepatocellular carcinoma and is
in several phase II studies in patients with gastrointestinal (GI)
tumors. This review describes the clinical development of
regorafenib in patients with GI cancers, and highlights the
key issues important for the modern day clinical pharmacist
who forms part of the multidisciplinary team ensuring safe
and effective delivery of the drug to the patient. This informa-
tion is considered of particular importance to the clinical
pharmacist for the future development of regorafenib in this
treatment setting.
Keywords Regorafenib .Multi tyrosine kinase inhibitor .
Pharmacist . Gastrointestinal tumors
Introduction
Gastrointestinal cancers comprise tumors of the gastrointesti-
nal tract including the esophagus, bowel, and rectum, and the
accompanying organs such as the stomach, liver, and pancre-
as. In 2008, there were approximately 3.9 million cases of
gastrointestinal cancer worldwide and approximately 2.8 mil-
lion deaths worldwide from the disease. Global incidence and
mortality rates of 54.9 and 39.4 cases per 100,000 respective-
ly, were reported [1].
The introduction of targeted agents either as monotherapy
or in combination with standard chemotherapy regimens has
improved clinical outcome in patients with gastrointestinal
cancer where they have become standard of care. VEGF-
targeting agents (monoclonal antibody [mAb] bevacizumab,
and a VEGFR decoy receptor, aflibercept) and EGFR mAbs
are approved for use in patients with metastatic colorectal
cancer (mCRC) [2–4]. The tyrosine kinase inhibitor (TKI)
imatinib targeted to activated KIT and PDGFRα receptors
[5] and the multikinase inhibitor (MKI) sunitinib [6] are
approved for use in patients with gastrointestinal stromal
tumors (GIST), and the MKI sorafenib [7] is considered
standard of care in previously untreated patients with hepato-
cellular carcinoma (HCC). However, there remains an unmet
need in those patients whose tumors are intrinsically resistant,
or that become resistant to the currently available treatments
[2, 8].
Regorafenib (BAY 73–4506, Stivarga®, Bayer HealthCare
Pharmaceuticals Inc.) is a novel MKI with a distinct and wide-
ranging profile of tyrosine kinase inhibition [9, 10]. It is the
first MKI to be approved for use in mCRC patients and has
also been approved in patients with advanced GIST
progressing on imatinib and sunitinib. Approval was granted
by the US Food and Drug Administration (FDA) for both
these indications [11]. An application for marketing authori-
zation has been submitted for the use of regorafenib in patients
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with advanced GIST, to the European Medicines Agency
(EMA), following recent EU approval of regorafenib in the
treatment of adult patients with mCRC who have been previ-
ously treated with, or are not considered candidates for, avail-
able therapies [12].
The modern day oncology clinical pharmacist is part of a
multidisciplinary team (MDT) providing a safe continuum of
care to the cancer patient in a new era of chemotherapy and
biological agents. In addition to formulation, dispensing and
disposing of cancer drugs, and the management of their cost
and reimbursement, the clinical pharmacist plays an increas-
ing role in the direct care of the patient. This includes the
provision of counseling for treatment compliance, for possible
drug-drug interactions, and for the potential side-effects and
management of occurring side-effects, in addition to the pro-
vision of medicines during patient follow-up, and providing
an education service for patients and health care providers
[13–15]. With the inclusion of regorafenib to the available
formulary for patients with gastrointestinal cancers this review
describes the clinical development of regorafenib in this treat-
ment setting, and highlights the key issues important for the
clinical pharmacist to ensure safe and effective delivery of the
drug to the patient.
Preclinical studies
Regorafenib is a fluoro-substituted omega-carboxylaryl
diphenyl urea [9]. Its biochemical profile is similar to but
distinct from sorafenib and it appears to be more pharmaco-
logically potent than sorafenib [9, 16] (Table 1). The major
metabolites, M-2 (N-oxide) and M-5 (N-oxide and N-
desmethyl) reportedly exhibit similar efficacy compared with
regorafenib in both in vitro and in vivo models [10, 17].
Analysis of the biochemical activity of regorafenib using
in vitro kinase assays demonstrated the inhibition of a large
set of kinases including angiogenic and stromal receptor tyro-
sine kinases (RTKs); VEGFR-1, -2, and -3, TIE2, FGFR-1,
and PDGFR-β at IC50 concentrations of 4–311 nM; oncogen-
ic RTKs, KIT, and RET, and the intracellular signaling kinases
cRAF/RAF-1, and both the wild-type and mutant forms of
BRAF (V600E) at IC50 concentrations of 1.5–28 nM [9].
Inhibition of additional kinases including DDR2, EphA2,
PTK5, p38α, and β occurred at <100 nM concentrations.
While inhibition was not demonstrated for other kinases
(EGFR, PKC, MET, ERK1/2, and AKT) using these assays
[9]. Cellular phosphorylation assays support the spectrum of
tyrosine kinase inhibition by regorafenib including inhibition
of MAPK, a component of an intracellular pathway important
in epithelial cell signaling and tumorigenesis [9].
The antiangiogenic properties of regorafenib were demon-
strated through the inhibition of cellular proliferation in stim-
ulated vascular cell lines (human umbilical vascular
endothelial cells), and through the recording of changes in
tumor vasculature (using dynamic contrast enhanced
magnetic resonance imaging, DCE-MRI) in rat glioblastoma
xenografts [9]. Further inhibitory effects on tumor cell prolif-
eration were shown in human hepatoma cell lines and in
human cancer cell lines harboring mutations in RTK genes
including, GIST (KIT K642E) and thyroid cancer (RET
C634WT) cell lines [9], and in drug-resistant GIST cell lines
harboring mutations in exon 11 of the KIT gene [18]. Inhibi-
tion of tumor growth and angiogenesis was further demon-
strated in tumor xenograft models of a range of human tumors,
including CRC, breast, and renal cell carcinoma (RCC) [9]. In
these studies, no animal lethality was reported. Regorafenib
was also shown to inhibit angiogenesis and metastasis in a
highly aggressive orthotopic colon cancer model [19].
Clinical development
Based on the encouraging preclinical data, phase I and II
studies were performed to establish a safe and potentially
effective dose for single-agent regorafenib in patients with
advanced solid tumors (summarized in Table 2).
The first-in-human phase I clinical trial in patients with
advanced solid tumors (mainly CRC), performed by Mross
et al., used a dose-escalation design to establish single-agent
oral regorafenib at 160 mg as the recommended dose for
future study in a schedule of daily administration for 21 days
(3 weeks), with 7 days off (1 week), in repeated 28-day
(4 week) cycles. This was based on dose-limiting toxicities
and the pharmacokinetic and safety profile [20]. This regimen
was confirmed as suitable in additional phase I and phase II
studies which concluded that single-agent regorafenib was
tolerable with promising activity in patients with refractory
Table 1 Biochemical activity of regorafenib and sorafenib
Mean IC50 (nM)±SD
Biological target Regorafenib Sorafenib
VEGFR-1 13±0.4 –
Murine VEGFR-2 4.2±1.6 15±6









BRAF V600E 19±6 38±9
IC50 half maximal inhibitory concentration
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Table 2 Phase I and II clinical studies of single-agent regorafenib in patients with solid tumors








mga/daily 21 days on





Mross et al. [20] DLT in cycle 1:
120 mg (n=3/8)b, 1 HFSR, 2 infections
160 mg (n=2/12), 1 allergic reaction, 1 vomiting
220 mg (n=5/12), 2 HFSR, 1 pruritus, 1
abdominal pain, 1 asthma
Grade 3/4 related AEc:
Any (49 %), HFSR (19 %), hypertension (11 %),
diarrhea (8 %), rash (6 %)
Response (n=47)d:






mg/daily 21 days on 7
days off Cohort
extension: 160 mg






DE (n=15) n=11 (29 %, 6/25 receiving 160 mg regorafenib)
Extension cohort
(n=23)
AE-related dose reduction/interruption: n=25 (66 %)
Grade 3 related AEc:
Any (58 %), HFSR (32 %), fatigue (11 %),
hypertension (11 %), rash (5 %)
Responsed (n=27):
1 PR, 19 SD, DCR 74 %, 7 PD











DLTs in cycle 1/2:
100 mg (n=2/11), 1 skin toxicity, 1
anemia/thrombocytopenia
120 mg (n=3/6), 2 skin toxicity, 1
thrombocytopenia
140 mg (n=4/10), 2 skin toxicity, 1 diarrhea, 1
hyperbilirubinemia/AST increase
Grade 3 related AEc: HFSR (11 %), pain (5 %)
Response (n=36)







(21 days on 7 days
off) (n=33)
Primary: CBRe Response (n=33):
George et al. [22] CBR 79 % (95 % CI 61–91)
4 PR, 22 SD ≥ 16 weeks
Median PFS: 10.0 months (95 % CI 8.3–14.9)
Safety:
AE-related dose reductions 27
Grade 3 AEc: Hypertension (36 %), HFSR
(24 %), hypophosphatemia (15 %), rash








(21 days on 7
days off) (n=36)
Primary: safety Safety:
Bruix et al. [24] AE-related dose reductions n=15
AE-related treatment interruptions n=32
Grade ≥3 related AE:
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mCRC [21], advanced GIST progressing on imatinib and
sunitinib [22, 23], and intermediate or advanced HCC
progressing after first-line sorafenib [24] (Table 2).
An alternative dosing regimen of daily 100mg single-agent
regorafenib, administered continuously in 3-week cycles was
also shown to be safe in patients with refractory solid tumors
[25].
Pharmacokinetic analysis from phase I and phase II studies
revealed a similar exposure at steady state for regorafenib
(detailed below) and its pharmacologically active metabolites
M-2 and M-5 [20, 21, 24].
The safety profile reported in many of these studies was
typical for that reported with MKI. Adverse events were
common but generally manageable with standard-of-care
practices, with few permanent discontinuations from treat-
ment, or deaths due to an adverse event reported. The most
commonly occurring grade 3/4 treatment-related toxicities
across studies included hand-foot skin reactions (HFSR), hy-
pertension, rash, and diarrhea (Table 2).
Activity from phase I and phase II studies reported mainly
prolonged stable disease with the disease control rates ranging
from 66 % to 74 % (Table 2). Data from these studies formed
the rationale for the pivotal phase III studies in mCRC and
GIST and an ongoing phase III study in HCC.
mCRC
A phase 1b study by Strumberg et al. investigated oral rego-
rafenib in 38 patients with chemorefractory mCRC, 15 re-
ceived a dose escalation (60–220 mg) of regorafenib and 23
(expansion cohort) received a dose of 160 mg. Regorafenib
was administered once daily for the first 3 weeks of each 4-
week cycle (Table 2). The authors reported a tolerable toxicity
profile and preliminary evidence of antitumor activity [21].
The disease control rate was 74 % (20 of 27 assessable
patients). On the basis of these results, and the high unmet
need in this population of patients, the decision was made to
precede to a randomized phase III trial.
The phase III CORRECT study (patients with metastatic
COloRectal cancer treated with REgorafenib or plaCebo after
failure of standard Therapy, BAY 73-4506/14387,
NCT01103323) investigated regorafenib in mCRC patients
previously treated with 5-fluorouracil (5-FU), irinotecan,
oxaliplatin, bevacizumab, and in patients with KRAS wild-
type tumors an EGFR mAb [26]. This was a placebo-
controlled double-blind trial at 114 centers in 16 countries
worldwide. Patients were ≥18 years of age, had an Eastern
Cooperative Oncology Group performance status (ECOG PS)
of 0 or 1, and a life expectancy of >3 months with documented
mCRC and progression during or within 3 months after the last
standard therapy. Patients were randomly assigned (2:1 and
stratified by previous treatment with VEGF-targeting drugs,
time from diagnosis of metastatic disease, and geographical
region) to receive best supportive care plus oral regorafenib
160 mg or placebo once daily, for the first 3 weeks of each 4-
week cycle. No crossover between patient groups was allowed.
Between April 30, 2010 andMarch 22, 2011, a total of 760
patients were randomly assigned to receive regorafenib (n=
505) or placebo (n=255), and 753 patients initiated treatment
(500 with regorafenib and 253 with placebo; population for
safety analyses). Baseline and disease characteristics were
similar in the treatment arms except more patients in the
placebo group had KRAS mutations (62 % vs 54 %). All
patients had received prior anti-VEGF treatment.
Table 2 (continued)
Study/reference Patients Treatment Objectives Main findings
Any (58 %), fatigue (17 %), HFSR (14 %),
diarrhea (6 %), hyperbilirubinemia (6 %)
hypophosphatemia (6 %)
Efficacy:
Median TTP 4.3 months (95 % CI 2.9–13.1)
Median OS 13.8 months (95 % CI 9.3–18.3)
Response (n=31)e:
1 PR, 25 SD, DCR 72 %, 5 PD
AE adverse events, CBR clinical benefit rate, DE dose escalation, GIST gastrointestinal tumors, HCC hepatocellular carcinoma, HFSR hand-foot skin
reaction, mCRC metastatic colorectal cancer, MTD maximum tolerated dose, ORR overall response rate, PFS progression-free survival, TTP time to
progression, OS overall survival, PD progressive disease, PK pharmacokinetics, PR partial response, SD stable disease
a Regorafenib was administered as an oral solution for dose-levels 10–120 mg and as co-precipitate tablet in ≥120 mg dose-level
b All using regorafenib solution, infections were later not considered dose limiting
cMost common treatment emergent (drug-related AEs) occurring in ≥5 % of patients
d Response in evaluable patients by RECIST
e Response in evaluable patients by modified RECIST
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The primary endpoint of overall survival was met at a
preplanned interim analysis after 432 deaths at a data cutoff
of July 21, 2011. Regorafenib demonstrated a significant 23%
reduction in the risk of death (Hazard ratio [HR] 0.77, 95%CI
0.64–0.94; one-sided p=0.0052).Median overall survival was
6.4 months in the regorafenib arm versus 5.0 months in the
placebo arm. In the regorafenib compared with placebo arms
the HR for progression-free survival (PFS) was 0.49 (95 % CI
0.42–0.58, p<0.0001). The objective response rates (all par-
tial responses) were comparable between the treatment arms
(1.0 % vs 0.4 %, p=0.19), however there was a significantly
higher disease control (partial response plus stable disease
after 6 weeks) in the regorafenib compared with placebo arm
(41 % vs 15 %, p<0.0001) [26].
Treatment-related adverse events of any grade occurred in
93 % of patients assigned to regorafenib and 61 % assigned to
placebo. The most common grade ≥3 regorafenib-related re-
actions were HFSR (17 %), fatigue (10 %), diarrhea (7 %),
hypertension (7 %), and rash or desquamation (6 %). In-
creased liver transaminases and bilirubin was higher in the
regorafenib group than the placebo group. This was mainly
due to grade 1 and 2 events. Eleven deaths were reported due
to adverse events not associated with disease progression,
eight (2 %) in patients treated with regorafenib (two for
pneumonia and two for gastrointestinal bleeding, and one each
for intestinal obstruction, pulmonary hemorrhage, seizure, and
sudden death) and three (1 %) in those receiving placebo (two
for pneumonia and one for sudden death). One fatal case
associated with regorafenib-related liver injury was first re-
ported 43 days after administration in a patient with liver
metastases who died 6 weeks later. Dose reductions (38 %
vs 3 %) and dose interruptions (61 % vs 22 %) were more
common in patients receiving regorafenib compared with the
placebo, mainly due to dermatological, gastrointestinal, con-
stitutional, and metabolic or laboratory events.
Changes in patient quality of life (QoL), as assessed using
the European Organization for the Research and Treatment of
Cancer QoL-C30 questionnaire and the EuroQoL-five dimen-
sion health utility index, were reportedly not different between
the regorafenib and placebo treatment arms over the treatment
period [27].
Based on the CORRECT study data, the EMA approved
the use of regorafenib in the treatment of adult patients with
mCRC who have been previously treated with, or are not
considered candidates for, available therapies (these include
fluoropyrimidine-based chemotherapy, an anti-VEGF therapy
and an anti-EGFR therapy) [10] with similar approval from
the FDA [11].
GIST
A phase II study by George et al. investigated single-agent
regorafenib in 33 patients with TKI-resistant GIST who
received a median of 8 treatment cycles (range 2–17), with a
median follow-up of 10.9 months [22] (Table 2). The clinical
benefit rate (CBR, defined as the proportion of patients with a
composite of complete response, partial response, and stable
disease lasting ≥16 weeks) with regorafenib was 79 % (95 %
CI 61–91), including four patients with partial response and
22 with stable disease lasting ≥16 weeks. Median PFS was
10.0 months (95 % CI 8.3–14.9). After a longer follow-up
(median duration of 20 months), a CBR of 81 %, median PFS
of 13months (95%CI 9–18), and a median overall survival of
27 months (95 % CI 16 to not reached) was reported [23].
On the basis of the preliminary data, and the preclinical
rationale of targeting the pathogenic mutant RTKs with a
structurally distinct small-molecule inhibitor, the phase III
GRID study (GIST—Regorafenib In progressive Disease,
NCT01271712) was performed to assess the efficacy and
safety of regorafenib in patients with metastatic or
unresectable GIST, progressing after failure of at least previ-
ous imatinib and sunitinib [28]. The double-blind placebo-
controlled GRID study was conducted at 57 hospitals in 17
countries worldwide [28]. Patients with histologically con-
firmed metastatic or unresectable GIST with at least one
measurable lesion, adequate organ function and ECOG PS
≤1, were randomly assigned to receive best supportive care
and either oral regorafenib 160 mg daily or placebo for the
first 3 weeks of a 4-week cycle.
From January 4 to August 18, 2011, 199 patients were
randomly assigned to best supportive care plus regorafenib
(n=133) or placebo (n=66), one patient in the regorafenib arm
did not receive treatment. The primary endpoint was PFS and
secondary endpoints included overall survival, time to pro-
gression, objective response rate and disease control rate. At
the data cutoff (January 26, 2012), PFS was significantly
longer in the regorafenib compared with the placebo arm
(median 4.8 vs 0.9 months, HR 0.27, 95 % CI 0.19–0.39,
p<0.0001). Following progression, 85 % of patients assigned
to placebo crossed over to regorafenib and this may have
accounted for the lack of a significant difference in overall
survival between the regorafenib and placebo arms (29 [22 %]
vs 17 [17 %] events, HR 0.77, 95 % CI 0.42–1.41, p=0.199).
Overall response rates were 4.5 % and 1.5 % (all partial
responses), and stable disease at any time and of any duration
occurred in 71.4 % and 33.3 % of patients in the regorafenib
and placebo arms, with reported disease control rates of 52.6
and 9.1 % respectively (p<0.0001).
The most common drug-related adverse events of any
grade in patients treated with regorafenib (56 %) and placebo
(14 %) were HFSR. Any grade ≥3 adverse events occurred in
61 % and 14 % of patients respectively, with the most com-
mon related to regorafenib being hypertension (23 %) and
diarrhea (5 %). There were ten deaths reported as related to
adverse events, three were deemed drug-related, two receiving
regorafenib (cardiac arrest and hepatic failures), and one
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treated with placebo (fatigue). Adverse events leading to dose
modifications were more frequent in patients treated with
regorafenib (72 %) than with placebo (26 %), although the
occurrence of adverse events leading to permanent discontin-
uation was similar (6 % vs 8 %) between the groups.
Data from the GRID study, in particular the fivefold in-
crease in PFS and the excellent disease control rate in patients
treated with regorafenib, led to the approval by the FDA of
regorafenib in treating patients with locally advanced,
unresectable, or metastatic GIST who have previously been
treated with imatinib mesylate and sunitinib malate [11].
HCC
A phase II study by Bruix et al. assessed safety (primary
endpoint) and efficacy (secondary endpoints) of single-agent
regorafenib in 36 patients with HCC and preserved to mildly
impaired liver function (Child-Pugh A), progressing on pre-
vious treatment with sorafenib (Table 2) [24]. The median
treatment duration was 19.5 weeks (range 2–103). At the data
cutoff, three patients remained on treatment. Reasons for
discontinuation were adverse events (56 %), disease progres-
sion (28 %), consent withdrawal (6 %) and death (3 %).
Among the 18 patients who stopped treatment due to adverse
events, 7 (19 %) were reported as drug-related. Seventeen
patients (47 %) required dose reductions (mostly for adverse
events [n=15]), 35 (97 %) patients had treatment interruption
(mostly for adverse events [n=32] or patient error [n=11]).
The most frequent (>5 %) treatment-related grade ≥3 adverse
events were fatigue (17 %), HFSR (14 %), diarrhea (6 %),
hyperbilirubinemia (6 %) hypophosphatemia (6 %). Disease
control was achieved in 26 patients (partial response n=1;
stable disease n=25). Median time to progression was
4.3 months (95 % CI 2.9–13.1) and median overall survival
was 13.8 months (95 % CI 9.3–18.3). Accounting for the fact
that these patients had tolerated prior treatment with sorafenib,
the authors found regorafenib to have acceptable and manage-
able toxicity profile, comparable with those reported for so-
rafenib in this setting [29]. No dose adjustment was recom-
mended in patients with mild or moderate hepatic impairment
[11, 24].
This phase II study provided the rationale for the phase III
RESORCE study (REgorafenib after SORafenib in patients
with hepatoCEllular carcinoma, NCT01774344) of regorafe-
nib after sorafenib in patients with hepatocellular carcinoma
[30]. The RESORCE study is a randomized, double-blind,
placebo-controlled multicenter phase III study of regorafenib
in patients with HCC after sorafenib. The study is currently
recruiting patients, of whom approximately 530 who meet the
entry criteria [30] will be randomly assigned in a 2:1 ratio to
regorafenib or placebo. The primary endpoint of the study is
overall survival. Secondary endpoints include objective tumor
response, PFS, time to tumor progression and disease control.
Study treatment arms are regorafenib 160 mg orally every day
for 3 weeks of every 4-week cycle plus best supportive care
and placebo for 3 weeks of every 4-week cycle (i.e. 3 weeks
on, 1 week off) plus best supportive care. The estimated
primary completion date is October 2015 (final completion
October 2016).
Clinical pharmacology of regorafenib
Mode of action and delivery
Regorafenib inhibits a wider spectrum of tyrosine kinase
targets involved in regulating angiogenesis and oncogenic
signaling compared with other inhibitors of angiogenesis such
as bevacizumab and aflibercept or other MKI such as
sorafenib.
Bevacizumab is a humanized monoclonal antibody to
VEGF-A and is indicated for use in a number of solid tumors
including mCRC, locally advanced or metastatic non-small-
cell lung cancer (NSCLC), metastatic breast cancer, metastatic
RCC and glioblastoma [31, 32]. Aflibercept (ziv-aflibercept in
the US) is a recombinant fusion protein consisting of the
second immunoglobulin (Ig) domain of VEGFR-1 and the
third Ig domain of VEGFR-2 fused to human Ig and exhibits
affinity for VEGF-A, VEGF-B and placental growth factor
[33]. Aflibercept is indicated for use in combination with
FOLFIRI in patients with mCRC progressing on oxaliplatin-
based chemotherapy [34, 35]. In comparison with these
agents, regorafenib inhibits a number of angiogenic specific
targets including VEGFR-1 -2, and -3, and TIE2 and stromal
RTKs PDGFRβ and FGFR-1. Furthermore, regorafenib ap-
pears to be a more potent inhibitor of oncogenic kinases
(BRAF V600E, RET, RAF-1 and KIT) than sorafenib [16,
21].
Regorafenib film-coated tablets should be swallowed
whole with water after a low-fat meal at the same time every
day (breakfast, <30 % fat) [10]. An example of a low-fat meal
would include one portion of cereal (about 30 g), one glass of
skimmed milk, one slice of toast with jam, one glass of apple
juice, and one cup of coffee or tea (520 cal, 2 g of fat). In a
food-effect study, 24 healthy men received a single 160 mg
dose of regorafenib on three separate occasions: under a fasted
state, with a high-fat meal and with a low-fat meal. A high-fat
meal (945 cal and 54.6 g fat) increased the mean area under
the plasma concentration vs time curve (AUC) of regorafenib
by 48 % and decreased the mean AUC of the M-2 and M-5
metabolites by 20 and 51 %, respectively, compared with the
fasted state. A low-fat meal (319 cal and 8.2 g fat) increased
the mean AUC of regorafenib, M-2, and M-5 by 36, 40, and
23 %, respectively compared with fasted conditions [11].
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As described previously the recommended dose and regi-
men is 160 mg (4 tablets of 40 mg) once daily for 21 days out
of 28 cycles. Treatment should be administered until disease
progression or the occurrence of unacceptable toxicity [10,
11].
Pharmacokinetic properties of regorafenib
Regorafenib is metabolized primarily in the liver by CYP3A4
(oxidative metabolism—special attention must be paid when
administering to patients receiving CYP3A4 inhibitors/
inducers as described below) and UGT1A9 (glucuronidation).
The main circulating metabolites of regorafenib in human
plasma, M-2 and M-5, are both pharmacologically active
and have similar concentrations to regorafenib at steady state.
The metabolites may be reduced or hydrolyzed in the gastro-
intestinal tract by microbial flora, allowing reabsorption of the
unconjugated active substances (enterohepatic circulation).
The pharmacokinetic data for regorafenib are based primarily
on preclinical data and data from phase 1 studies [10, 11, 20,
21].
Absorption Following a single oral dose of 160 mg given to
patients with solid tumors, regorafenib reaches a geometric
mean peak plasma level (Cmax) of 2.5 μg/mL at a median time
of 4 h, and a mean AUC of 70.4 μg h/mL.
Distribution Plasma concentration–time profiles for regoraf-
enib and M-2 and M-5 showed multiple peaks across the 24-h
dosing interval (attributable to enterohepatic circulation). In
vitro protein binding of regorafenib, M-2, and M-5 to human
plasma proteins is high at 99.5, 99.8, and 99.95 %,
respectively.
Elimination Following oral administration (160 mg), the
mean elimination half-lives for regorafenib andM-2 in plasma
are similar at 28 h (range 14–58) and 25 h (range 14–32),
respectively. The mean elimination half-life for M-5 is longer
at 51 h (range 32–70). Studies using a radiolabeled oral
solution of regorafenib (120 mg) showed that approximately
90 % of the radioactive dose was recovered within 12 days of
administration, with about 71 % of the dose excreted in feces
(47 % as parent compound, 24 % as metabolites), and about
19 % of the dose excreted in urine as glucuronides. Urinary
excretion of glucuronides decreased below 10 % under
steady-state conditions.
Linearity/non-linearity Systemic exposure of regorafenib at
steady-state increases in a dose proportional manner up to
60 mg doses, but at doses >60 mg there is a lack of dose
proportional increases. Accumulation of regorafenib at steady
state results in an approximately two-fold increase in plasma
concentrations, which is consistent with the elimination half-
life and dosing frequency. After oral administration of 160 mg
regorafenib, at steady state, regorafenib reaches mean peak
plasma levels of approximately 3.9 μg/mL (8.1 μM) and a
geometric mean AUC of 58.3 μg h/mL. The coefficient of
variation for AUC and Cmax is between 35 and 44 %. The
peak-to-trough ratio of mean plasma concentrations is <2.
Both M-2 and M-5 metabolites exhibit non-linear accumula-
tion, which might be caused by enterohepatic recycling, or
saturation of the UGT1A9 pathway. Whereas plasma concen-
trations of M-2 and M-5 after a single dose of regorafenib are
much lower than those of the parent compound, the steady-
state plasma concentrations of M-2 (3.3 μg/mL) and M-5
(2.9 μg/mL) are comparable with those of regorafenib.
The Strumberg phase 1 study in mCRC reported a similar
pharmacokinetic profile for regorafenib and its metabolites as
described. In the expansion cohort of patients treated with
160 mg of regorafenib, at steady state, systemic exposure of
M-2 (48 μg h/mL) and M-5 (65–79 μg h/mL) were similar to
that recorded for parent regorafenib (45–50 μg h/mL) [21].
A population pharmacokinetic model was used to investi-
gate the effects of patient demographics (sex, weight, body
mass index, height, and ethnic group) and baseline parameters
(kidney and liver function test, protein levels and hematocrit/
hemoglobin levels) on drug exposure in the CORRECT study
[36]. The model for regorafenib,M-2, andM-5 was developed
with NONMEM, based on pharmacokinetic data from a
densely sampled, open-label, phase I dose-escalation study
of regorafenib in 67 patients with advanced solid tumors. This
model was subsequently applied to the sparsely sampled
CORRECT study. The pharmacokinetics of regorafenib,
M-2, and M-5 were described by a two-compartmental model
that provided an adequate fit of the plasma concentration–time
profiles from both studies. Derived pharmacokinetic parame-
ter estimates were used to calculate the individual exposure
(Cavmd) of regorafenib, M-2, and M-5 in the CORRECT
study. Overall, a moderate to high variability in the regorafe-
nib pharmacokinetics was observed in the CORRECT study,
with a coefficient of variance of clearance of 44 % and even
higher variability in exposure toM-2 andM-5. Analysis of the
CORRECT study showed that higher bilirubin levels at base-
line were associated with higher individual exposure of rego-
rafenib and M-2 (Cavmd −14 to +18 %) when comparing the
5th and 95th percentiles of the observed bilirubin distribution
to the median baseline bilirubin levels, the overall variability
was −48.7 to +79.9 %. Higher body weight was associated
with lower exposure of M-2 and M-5, and exposure of M-5
was higher in women (Cavmd 77 %) than in men (the overall
variability of M-2 and M-5 were −69.8 to +149 % and −89.2
to +348 %, respectively). The magnitude of observed covar-
iate effects however was small compared with the overall high
variability in exposure. The other tested covariates did not
have an impact. The authors concluded that the effects of the
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covariates tested in population pharmacokinetic analysis of
the CORRECT data were not considered clinically relevant in
light of the overall high variability in exposure [36].
Drug-drug interactions of regorafenib
There is potential for drug-drug interactions when administer-
ing regorafenib [10, 11]. Co-administration with strong in-
ducers of cytochrome P-450 (CYP) 3A4 such as rifampicin,
phenytoin, carbamazepine, phenobarbital, and St John’s Wort
should be avoided. Co-administration with rifampicin
(600 mg for 9 days in 22 healthy male volunteers) with a
single dose of regorafenib (160 mg on day 7) was associated
with a reduction in the AUC of regorafenib of approximately
50 % and a three- to four-fold increase in exposure to the M-5
metabolite, but with no change in exposure to the M-2
metabolite.
Administration of ketoconazole (400 mg for 18 days), a
strong CYP3A4 inhibitor, with a single dose of regorafenib
(160 mg on day 5) in 18 healthy male volunteers resulted in an
increase in the mean exposure (AUC) of regorafenib of ap-
proximately 33 %, and a decrease in mean exposure to the
M-2 and M-5 metabolites of approximately 90 %. It is rec-
ommended that the concomitant use of strong inhibitors of
CYP3A4 activity (e.g., clarithromycin, grapefruit juice,
itraconazole, ketoconazole, posaconazole, telithromycin, and
voriconazole) is avoided as their influence on the steady-state
exposure of regorafenib and its metabolites has not been
studied.
In vitro study data also suggest an interaction between
regorafenib and warfarin. In patients with advanced solid
tumors administered a single oral dose of 10 mg of warfarin
(substrate of CYP2C9) 1 week before and 2 weeks after
regorafenib (160 mg once daily) the mean AUC of warfarin
increased by 25 %.
Data from in vitro studies indicate that regorafenib andM-2
inhibit glucuronidation mediated by UGT1A1 and UGT1A9
whereas M-5 only inhibits UGT1A1 at concentrations which
are achieved in vivo at steady state [10]. In a phase Ib study of
regorafenib in combination with FOLFIRI or FOLFOX in
patients with mCRC, administration of regorafenib with a 4-
day break prior to administration of irinotecan resulted in a
significant increase in irinotecan and its metabolite SN-38 (a
substrate of UGT1A1). For irinotecan and SN-38, the AUC
following exposure to regorafenib in cycle-2 was significantly
higher than prior to regorafenib dosing in cycle-1, the ratios of
AUC values (cycle-2:cycle-1) were 1.28 (95 % CI 1.06–1.54)
and 1.44 (95 % CI 1.12–1.85), respectively [37]. This sug-
gests that co-administration of regorafenib may increase sys-
temic exposure to UGT1A1 and UGT1A9 substrates.
In vitro data suggest that regorafenib is an inhibitor of
breast cancer resistance protein (BCRP) (ABCG2, IC50 values
40–70 nM) and P-glycoprotein (ABCB1, IC50 value
approximately 2 μM). Co-administration of regorafenib may
increase the plasma concentrations of concomitant BCRP
substrates, such as methotrexate, or P-glycoprotein substrates,
such as digoxin.
Tolerability and monitoring
The overall safety profile of regorafenib is based on data from
more than 1,200 cancer patients (all types of cancer) treated in
clinical trials [10, 11]. The most frequently observed drug-
related adverse events (≥20 %) are asthenia/fatigue, decreased
appetite and food intake, HFSR, diarrhea, weight loss, infec-
tion, hypertension and dysphonia. The most serious adverse
events are severe liver injury, hemorrhage, and gastrointestinal
perforation. Adverse events that carry a specific warning and/
or specify precautions in the regorafenib prescribing informa-
tion, which may require monitoring leading to dose modifica-
tions or treatment discontinuation, are summarized in Table 3.
Data from the CORRECT study report that the most com-
mon adverse events including diarrhea, fatigue, HFSR, hyper-
tension, and rash occurred early during treatment and that
close early monitoring of adverse events and management
by dose modification is recommended [38].
The incidence of HFSR is commonly increased in cancer
patients treated with regorafenib. A meta-analysis [39] of
1,078 patients treated with regorafenib from four studies [24,
26, 28, 40] reported that the relative risk (RR) of all grade (RR
=5.4, 95 % CI 3.76–7.76, p<0.001) and high grade (RR=
41.99, 95 % CI 5.88–299.93, p<0.001) HFSR was signifi-
cantly increased in patients treated with regorafenib compared
with controls. In this analysis, the incidence of HFSR varied
with tumor type; 71.4 % for RCC, 60.2 % for GIST, 50 % for
HCC and 46.6 % mCRC. The mechanism for HFSR in
patients treated with regorafenib is not known but the occur-
rence of HFSR appears to be a class effect for MKI [39].
Clinically, HFSR patients initially present with erythema and
dysesthesia on the palms and soles (areas of mechanical stress)
followed by painful sharply demarcated erythema and callus-
like thickening. Large, painful blisters may also form in more
severe cases. HFSR can be managed by the prophylactic and
therapeutic use of cotton socks and gloves, gel inserts, soft
footwear and pedicures for calluses. The treatment of symp-
toms often includes the use of topical applications with mois-
turizing creams and soaps, keratolytics (e.g., urea, salicylic
acid), and the use of cold immersions and pain relief medica-
tion to ease the pain. Severe reactions may require dose
modifications, interruptions, or even discontinuation (Table 3).
HFSR appears to be one of the most common reasons for dose
reductions of regorafenib [22, 40, 41] however; dose re-
escalations appear to be tolerated [22].
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Table 3 Warnings and precautions for serious adverse events in gastrointestinal cancer patients treated with regorafenib [10, 11]
Warning Comments [references] Precautions
Hepatotoxicity Fatal drug induced liver injury was reported in
0.3 % of 1,200 regorafenib-treated patients
Monitor hepatic function (ALT/AST/bilirubin levels) prior to and during
treatment with regorafenib
Prescribing information contains a warning for
hepatotoxicity [11]
Grade 1–2a (any occurrence):
Continue treatment with weekly monitoring until grade 1 or baseline
is returned
Grade 3a (1st occurrence):
Interrupt treatment and apply weekly monitoring until grade 1 or
baseline is returned. Restart at reduced dose by 40 mg and monitor
weekly for 4 weeks. If re-occurrence then discontinue treatment
Grade 4a (any occurrence): Permanently discontinue
Grade 2a or higher with concurrent bilirubin >2×ULN (any occurrence):
Permanently discontinue regorafenib and monitor liver function weekly
until resolution or return to baselineb
Hemorrhage Increased incidences of hemorrhage (any grade)
were reported in regorafenib vs placebo arms
in the CORRECT study (21 % vs 8 %) and the
GRID study (11 % vs 3 %). Fatal hemorrhage
occurred in 0.6 % (4/621) of regorafenib-treated
patients in both studies, sites included respiratory,
gastrointestinal and genitourinary tracts [26, 28]
Monitor blood counts and coagulation parameters in patients with
conditions predisposing to bleeding or treated with anticoagulants
(e.g. warfarin) or concomitant medicines that increase risk of bleeding




Treatment with regorafenib induces a high incidence
of dermatological toxicity mainly HFSR.
Increased incidences of HFSR (any grade) were
reported in regorafenib vs placebo arms in the
CORRECT (45 % vs 7 %) and the GRID studies
(67 % vs 12 %). Most cases occur in the first
treatment cycle [26, 28]
Preventative measures:
Control of calluses, use of shoe cushions and gloves to prevent pressure
stress to soles and palms
Management of HFSR:
Use of keratolytic creams and moisturizing creams/soaps on affected
areas. Cold can be applied and acetaminophen can be given to reduce
pain
Dose modifications:
Grade 1 (any occurrence):
Maintain dose-level and apply symptom relief
Grade 2:
1st occurrence: decrease dose by 40 mg, apply supportive measures. If no
improvement interrupt treatment for 7 days until toxicity resolves to
grade 0–1. Dose-escalate at physician’s discretion
No improvement/2nd occurrence: Interrupt until toxicity resolves
to grade 0–1. Decrease dose by 40 mg on restarting. Dose-escalate at
physician’s discretion
3rd occurrence: Repeat as above
4th occurrence: Permanently discontinue treatment
Grade 3:
1st occurrence: apply supportive measures immediately, interrupt
treatment for 7 days until toxicity resolves to grade 0–1. Decrease dose
by 40 mg on restarting. Dose-escalate at physician’s discretion
2nd occurrence: as above but dose escalation not permitted
3rd occurrence: permanently discontinue treatment
Hypertensionc Hypertensive crisis was reported in 0.25 % of
1,200 treated patients in clinical trials. Most
cases occur during the first treatment cycle
[26, 28]
Regorafenib should only be administered to patients with controlled blood
pressure
Blood pressure should be monitored for the first 6 weeks of treatment and
then per cycle, or more frequently as clinically indicated
In cases of severe or persistent hypertension (grade 2) treatment should be
interrupted and the dose reduced at the discretion of the physician
Treatment should be discontinued for hypertensive crisis
Cardiac ischemia
and Infarction
In the CORRECT study the incidence of cardiac
ischemia and infarction was increased in
Patients with a history of ischemic heart disease should be monitored
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Biochemical (hypophosphatemia, hypocalcemia,
hyponatremia, and hypokalemia) and metabolic laboratory
abnormalities (increases in thyroid stimulating hormone, li-
pase and amylase) have been reported in patients treated with
regorafenib [22, 26, 40]. It is recommended to monitor bio-
chemical and metabolic parameters during regorafenib treat-
ment and to apply appropriate replacement therapy if required.
Dose reduction or modification, or in severe or persistent
cases discontinuation, should be considered.
Instances where regorafenib doses should be interrupted,
reduced, or discontinued are summarized in Table 4.
For populations that might be less tolerant to exposure to
regorafenib, animal studies have reported regorafenib to be
embryolethal, and teratogenic, with increased incidences of
cardiovascular, genitourinary and skeletal abnormalities found
in the fetuses from animals exposed to the drug. Advice of
these risks should be provided to patients of reproductive age,
and special appraisal of the harm to the fetus should be
undertaken if the patients become pregnant during treatment.
No clinically important differences in the mean exposure of
regorafenib or the active metabolites M-2 and M-5 were
observed in patients with HCC and mild (Child-Pugh A) or
moderate (Child-Pugh B) hepatic impairment compared with
patients with normal hepatic function. No dose adjustment is
recommended in patients with mild or moderate hepatic im-
pairment [11, 24]. However, it is recommended that patients
with hepatic impairment are closely monitored for adverse
reactions. Regorafenib is not recommended for use in patients
with severe hepatic impairment (Child-Pugh C), as it has not
been studied in this population.
No clinically relevant differences in the mean exposure of
regorafenib and the active metabolites M-2 and M-5 were
observed in patients with mild renal impairment (CLcr 60–
89 mL/min) compared to patients with normal renal function
following regorafenib 160 mg daily for 21 days. No dose
adjustment is recommended for patients with mild renal im-
pairment. Limited pharmacokinetic data are available from
patients with moderate renal impairment (CLcr 30–59 mL/
min). Regorafenib has not been studied in patients with severe
renal impairment or end-stage renal disease.
In the CORRECT and GRID studies in subgroup analyses,
no differences in safety and efficacy of regorafenib were
observed in patients <65 years compared with patients
≥65 years of age, or in those of different ethnic origins [28,
38, 42].
Perspectives
In the current treatment landscape in which regorafenib is
approved for use, there are specific considerations for the
clinical pharmacist to ensure its safe and effective use.
Table 3 (continued)
Warning Comments [references] Precautions
patients treated with regorafenib vs placebo
(1.2 % vs 0.4 %) [26]
Treatment should be interrupted in patients who develop cardiac
ischemia and or infarction. Reintroduction on physician’s discretion.
If no resolution treatment should be discontinued
RPLS RPLS diagnosed by MRI occurred in 1/1,200
regorafenib-treated patients [11]
If patients present with seizures, headache, visual disturbances,
confusion or altered mental state, evaluate for RPLS




Gastrointestinal perforation or fistula was reported
in 0.6 % of 1,200 patients in clinical trials and
in 2.1 % (4/188) of regorafenib-treated patients
in the GRID study: of these patients 2 cases of
gastrointestinal perforation were fatal [28]
Regorafenib should be permanently discontinued in patients who
develop gastrointestinal perforation or fistula
Wound healing
complications
No formal studies with regorafenib have been
reported. Inhibition of VEGFR can impair
would healing [11]
Treatment with regorafenib should be stopped 2-weeks before surgery
Resumption of treatment after surgery should be on clinical judgment
of adequate wound healing
Regorafenib should be discontinued in patients with wound dehiscence
Adverse events were graded according to NCI CTCAE
ALT alanine aminotransferase, AST aspartate aminotransferase, HFSR hand-foot skin reaction,MRImagnetic resonance imaging, NCI CTCAENational
Cancer Institute Common Terminology Criteria for Adverse Events, RPLS reversible posterior leukoencephalopathy syndrome, ULN upper limit of
normal
a NCI CTCAE grading for liver toxicity based on ASTand or ALT levels; grade 1<3 times ULN; grade 2>3 times to≤5 times ULN; grade 3>5 times to
≤20 times ULN; grade 4>20 times ULN
bException for patients with Gilbert’s syndrome who develop elevated transaminases should bemanaged as per the above outlined recommendations for
the respective observed elevation of ALT and/or AST
c To be managed using standard medical practice
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Pharmacists should provide advice on drug administration,
including patient counseling regarding strict adherence to the
regorafenib oral regimen, where tablets are to be taken every
morning with a low-fat meal. Regorafenib tablets should be
swallowed whole, not crushed or chewed, and patients should
avoid overdosing if a previous dose is missed. Advice should
also be provided by the pharmacist about potential drug-drug
interactions with regorafenib, and a thorough medication pro-
file review of the patient should be undertaken. Regorafenib
may increase exposure of drugs metabolized by specific
CYP450 enzymes (2B6, 2C8, 2C9, 2C19, 2D6, and 3A4)
and UGT1A1 and 1A9 enzymes. Regorafenib concentrations
may be increased or decreased by CYP3A4 inhibitors or
inducers. Patients should be advised to alert their health care
provider if they take any new medications, vitamins or herbal
products, and food (especially grapefruit juice).
Patients should also be counseled on the risk of serious
adverse events associated with regorafenib and advice should
be give to health care providers on patient monitoring. There
are specific warnings and precautions for the use of regoraf-
enib (detailed in Table 3). In patients with HCC, liver failure is
a major concern and severe drug-related toxicities have been
reported in trials of other MKI in HCC [43]. However, in the
phase II study by Bruix et al. regorafenib was tolerated in
patients with mild- or moderate hepatic impairment [11, 24].
Recommendations are that hepatic toxicity should be moni-
tored at baseline and throughout treatment.
Regorafenib-related HFSR is manageable by prophylactic
measures, the treatment of symptoms, and the use of treatment
interruptions and dose reductions. Patients appear to tolerate
resumption of treatment and escalation of dose. Patients
should be advised for symptoms of hypertension that include
severe headache, light-headedness, and neurological symp-
toms, and their blood pressure should be monitored through-
out treatment. Patients should be counseled on the increased
risk of bleeding/hemorrhage and should be advised to inform
their healthcare provider to any surgical procedure while on
regorafenib, or if they have recently undergone a surgical
procedure while initiating regorafenib. The increased risk of
cardiac toxicity, myocardial ischemia, and/or infarction,
should be highlighted with dizziness, chest pain, or dyspnea
indicated as symptoms.
In specific patient populations, advice should be given to
patients of reproductive age to avoid pregnancy. Regorafenib
appears to be safe and effective in patients <65 and ≥65 years
of age, [26, 28, 42], but there are little data in patients
≥75 years old. Regorafenib is effective in Asian patients in
subgroup analyses of randomized clinical trials [26, 28]. The
CONCUR clinical trial is currently investigating the efficacy
and safety of regorafenib in an Asian population [44].
Future development of regorafenib in gastrointestinal
cancers
A number of studies are investigating the positioning of
single-agent regorafenib in patients with gastrointestinal can-
cers. In patients with mCRC in the CORRECT study, sub-
group analysis demonstrated regorafenib to be active irrespec-
tive of the KRAS or BRAF tumor mutation status [26]. An
ongoing trial is investigating regorafenib in combination with
FOLFIRI in mCRC patients whose tumors harbor mutations
at codons 12 and 13 (exon 2) of the KRAS gene or codon 600
(exon 15) of the BRAF gene, previously treated with
FOLFOX [45]. If this is proven to be effective, this would
have important implications for the use of regorafenib in
patients with KRAS exon 2 mutated tumors where EGFR
mAbs have previously been proven to be ineffective [2–4].
Recent data also indicate that patients with tumors harboring
any RAS mutations (any mutations at specific codons within
exons 2–4 of the KRAS or the NRAS gene) do not benefit from
treatment with EGFR mAbs [46].
Previous reports from theML18147 (with bevacizumab) and
VELOUR (with aflibercept) studies [34, 47] suggest that post
Table 4 Summary of regorafenib dose modifications
Dose modification Reason
Dose interruption NCI CTCAE grade 2 HFSR; recurrent or failing to
improve within 7 days (despite dose reduction)
NCI CTCAE grade 3 HFSR; interrupt for a
minimum of 7 days
Symptomatic grade 2 hypertension
Any NCI CTCAE grade 3 or 4 AE
Dose reduction
to 120 mg
First occurrence of grade 2 HFSR of any duration
After recovery of any grade 3 or 4 AE
Grade 3 AST/ALT elevation; only to be resumed if




Re-occurrence of grade 2 HFSR at the 120 mg dose
After recovery of any grade 3 or 4 AE at the
120 mg dose (except hepatotoxicity)
Discontinue Failure to tolerate an 80 mg dose
Any occurrence of grade 4 hepatotoxicity
(AST or ALT >20×ULN)
Any occurrence of grade hepatotoxicity (AST or
ALT >3×ULN with concurrent bilirubin>2
times ULN)
Re-occurrence of grade 3 hepatotoxicity (AST or
ALT more than 5 times ULN) despite dose
reduction to 120 mg
Any grade 4 AE; only to be resumed if the potential
benefit outweighs the risks
AE adverse event, ALT alanine aminotransferase, AST aspartate amino-
transferase, HFSR hand-foot skin reaction, NCI CTCAE National Cancer
Institute Common Terminology Criteria for Adverse Events, ULN upper
limit of normal
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progression use of anti-angiogenesis therapy appears to be a
successful strategy for treating chemorefractory mCRC. Analy-
sis from the CORRECTand GRID studies appear to support the
use of regorafenib in patients progressing on previous anti-
angiogenesis therapy in mCRC (progressing on bevacizumab)
and GIST (progressing on sunitinib), respectively.
In the adjuvant treatment setting, the COAST study is a
randomized double-blind placebo-controlled phase III
study (currently registered, not yet open for recruitment)
investigating regorafenib as adjuvant therapy for CRC with
resected liver metastases. This trial aims to evaluate the
efficacy and safety of regorafenib (160 mg for 3 weeks of
a 4-week cycle) compared with placebo in CRC patients
after curative resection of their liver metastases and com-
pletion of all planned chemotherapy. The primary endpoint
is disease-free survival. The enrollment of 750 patients is
estimated with an expected completion date of September
2021 [48].
There are currently no predictive biomarkers to identify
those patients who will benefit from regorafenib in gastroin-
testinal cancers. Prespecified biomarker analysis is planned
for the CONCUR study of best supportive care plus regoraf-
enib or placebo in Asian mCRC patients who have progressed
on standard therapy [44]. A phase II study is underway to
determine the efficacy of single-agent regorafenib, and to
identify biomarkers in mCRC patients who have failed one
prior treatment for mCRC [49]. The estimated enrollment is
for 52 patients with a final completion date December 2017
(primary date March 2017).
The REFRAME study is currently recruiting to investigate
the efficacy and safety of single-agent regorafenib in previ-
ously untreated patients with mCRC who are frail or unsuit-
able for polychemotherapy regimens. The primary endpoint is
PFS at 6 months [50] and the estimated primary completion
date is June 2015.
Regorafenib dose and combination with standard che-
motherapy regimens is also under investigation. Promis-
ing efficacy and safety has been reported with 100 mg
daily regorafenib in a continuous schedule [25, 41]. The
flexibility of regorafenib dosing is apparent when used
in combination with irinotecan- or oxaliplatin-based che-
motherapy [37, 45, 51].
FOLFIRI and FOLFOX are standard chemotherapy regi-
mens in CRC [3]. A phase 1b study by Schultheis et al.
investigated regorafenib in combination with FOLFOX or
FOLFIRI in patients with mCRC [37]. Safety and pharmaco-
kinetics were primary objectives and tumor response was a
secondary objective. Forty-five patients were treated with
FOLFOX or FOLFIRI every 2 weeks; on days 4–10, patients
received regorafenib 160 mg orally once daily. The median
duration of treatment was 108 days (range 2–345 days). Treat-
ment was stopped for adverse events or death (17 patients),
disease progression (11 patients), and consent withdrawal or
investigator decision (11 patients). Six patients remained on
regorafenib at data cutoff (two without chemotherapy). Drug-
related adverse events occurred in 44 patients (grade ≥3 in 32
patients: mostly neutropenia [17 patients] and leukopenia,
HFSR, and hypophosphatemia [four patients each]). Thirty-
three patients (87 %) achieved disease control (partial re-
sponse or stable disease) for a median of 126 (range 42–
281) days. Regorafenib had acceptable tolerability in combi-
nation with chemotherapy, with increased exposure of
irinotecan and SN-38 but no significant effect on 5-
fluorouracil or oxaliplatin pharmacokinetics. This study pro-
vided the rational for a randomized placebo-controlled phase
II trial of regorafenib plus FOLFIRI compared with placebo
plus FOLFIRI in patients with mCRC progressing on
oxaliplatin-based chemotherapy. The primary endpoint is
PFS, with expected enrolment of 240 patients and completion
date of February 2021 [45].
The CORDIAL study was a single-arm phase II study
which investigated regorafenib in combination with
mFOLFOX6 in patients with previously untreated mCRC
(primary completion date March 2012, final completion date
April 2014) [51, 52]. The treatment combination had an
acceptable toxicity profile with some efficacy. Fifty three
patients received mFOLFOX6 on days 1 and 15, and regoraf-
enib (160 mg) on days 4–10 and 18–24 of each 4-week cycle.
The best overall response rate (in 41 evaluable) patients was
44 % (95 % CI 28–60), all were partial responses and 17
patients had stable disease with a median duration of
7.6 months (95 % CI 5.5–8.5). The disease control rate was
85 % (95 % CI 71–94). Median PFS in the ITT population (n
=54) was 8.5 months (95 % CI 7.4–11.3). At the time of the
data cutoff (November 15, 2012) median overall survival
had not been reached. The most common reported grade
≥3 adverse events were decreased neutrophil count
(40 %), hypertension (28 %), diarrhea (23 %), increased
serum lipase (19 %), and hypophosphatemia and periph-
eral neuropathy (13 %). Regorafenib was permanently
discontinued in four patients with dose reductions and
dose interruptions recorded in 24 (45 %) and in 47
(89 %) patients respectively.
Regorafenib is in clinical development in other
gastrointestinal-related cancers. As described previously, fol-
lowing encouraging phase II study data [24], the phase III
RESORCE study is investigating single-agent regorafenib in
patients with advanced HCC [30]. Single-agent regorafenib is
also under investigation in the randomized phase II INTE-
GRATE study of regorafenib versus placebo in patients with
advanced esophagogastric cancer performed by the Australian
Gastrointestinal Trials Group [53]. Finally, a randomized
phase II study is investigating regorafenib in combination with
FOLFOX in patients with unresectable or metastatic
esophagogastric cancer (estimated primary completion date
July 2015) [54].
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Summary
Single-agent regorafenib is an oral multikinase inhibitor ap-
proved for use in the continuum of care in patients with
mCRC and GIST. It is administered at 160 mg daily for the
first 21 days of a 28-day cycle. It is currently being investi-
gated in phase III study of patients with HCC, and in phase II
studies in patients with advanced unresectable or metastatic
esophagogastric cancer. Understanding the pharmacokinetics,
efficacy, and safety profile of single-agent regorafenib will
ensure that the oncology clinical pharmacist is able to contrib-
ute in theMDT to the safe and efficient delivery of regorafenib
in gastrointestinal cancer patients. This information is impor-
tant to the clinical pharmacist for the future development of
regorafenib in this treatment setting.
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